Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.8452
+0.0351 (4.33%)
At close: Aug 1, 2025, 4:00 PM
0.8385
-0.0067 (-0.79%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Virax Biolabs Group Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Virax Biolabs Group stock has a target of 3.00, which predicts a 254.95% increase from the current stock price of 0.85.

Price Target: $3.00 (+254.95%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$3.00$3.00$3.00$3.00
Change+254.95%+254.95%+254.95%+254.95%
* Price targets were last updated on Mar 31, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Virax Biolabs Group is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJun '25Jul '25
Strong Buy11
Buy00
Hold00
Sell00
Strong Sell00
Total11

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$3
Strong BuyInitiates$3+254.95%Mar 31, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
13.76M
from 6.33K
Increased by 217,274.82%
Revenue Next Year
4.08M
from 13.76M
Decreased by -70.35%
EPS This Year
0.04
from -1.62
EPS Next Year
n/a
from 0.04
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingMar 31, 2021Mar 31, 2022Mar 31, 2023Mar 31, 2024Mar 31, 2025Mar 31, 2026Mar 31, 2027
Revenue
123.82K-8.56K156.42K6.33K13.76M4.08M
Revenue Growth
23.97%--1,727.11%-95.95%217,274.82%-70.35%
EPS
-2.71-1.79-5.13-3.36-1.620.04-
EPS Growth
-------
Forward PE
-----20.72-
No. Analysts
-----33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027
High14.2M4.2M
Avg13.8M4.1M
Low13.2M3.9M

Revenue Growth

Revenue Growth20262027
High
223,671.9%
-69.5%
Avg
217,274.8%
-70.4%
Low
208,745.4%
-71.5%

EPS Forecast

EPS2026
High0.04
Avg0.04
Low0.04

EPS Growth

EPS Growth2026
High-
Avg-
Low-
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.